Published in Nat Med on November 07, 2011
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat Mater (2013) 2.32
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 2.21
Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell (2014) 1.83
Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev (2012) 1.71
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem (2013) 1.62
Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta (2014) 1.53
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. BMC Cancer (2014) 1.52
The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr (2012) 1.46
Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater (2012) 1.41
RERG suppresses cell proliferation, migration and angiogenesis through ERK/NF-κB signaling pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res (2017) 1.41
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. J Clin Invest (2016) 1.39
Extracellular vesicles: emerging targets for cancer therapy. Trends Mol Med (2014) 1.35
Oxidative stress, tumor microenvironment, and metabolic reprogramming: a diabolic liaison. Int J Cell Biol (2012) 1.29
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat Med (2012) 1.26
AEG-1/MTDH/LYRIC: signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis. Adv Cancer Res (2013) 1.26
Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh Migr (2012) 1.24
The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 1.21
MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res (2013) 1.19
Inflammation and oxidative stress in angiogenesis and vascular disease. J Mol Med (Berl) (2013) 1.15
Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol (2015) 1.15
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res (2013) 1.14
Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol Sin (2013) 1.11
Cancer metabolism and elevated O-GlcNAc in oncogenic signaling. J Biol Chem (2014) 1.11
Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PLoS One (2013) 1.09
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol (2013) 1.05
Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol (2014) 1.04
Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol (2012) 1.02
MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PLoS One (2013) 1.02
Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials (2012) 1.02
Tumor macroenvironment and metabolism. Semin Oncol (2014) 1.01
Adipocytes: impact on tumor growth and potential sites for therapeutic intervention. Pharmacol Ther (2013) 1.00
PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet (2013) 1.00
Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis (2014) 1.00
Metastatic tumors to the jaws and mouth. Head Neck Pathol (2014) 1.00
Extracellular Vesicles: Satellites of Information Transfer in Cancer and Stem Cell Biology. Dev Cell (2016) 0.99
In vitro inhibition of angiogenesis by antibodies directed against the 37kDa/67kDa laminin receptor. PLoS One (2013) 0.99
Transforming growth factor β-regulated microRNA-29a promotes angiogenesis through targeting the phosphatase and tensin homolog in endothelium. J Biol Chem (2013) 0.99
VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer. PLoS One (2013) 0.97
Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J Extracell Vesicles (2013) 0.97
Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets (2012) 0.97
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol (2013) 0.97
Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther (2013) 0.96
The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis (2012) 0.96
LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1α activation. J Exp Clin Cancer Res (2016) 0.96
Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget (2015) 0.95
Clinical and biological implications of the tumor microenvironment. Cancer Microenviron (2012) 0.95
Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection. Radiology (2014) 0.95
Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoS One (2014) 0.95
Adipose tissue angiogenesis: impact on obesity and type-2 diabetes. Biochim Biophys Acta (2013) 0.94
Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist (2013) 0.94
Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics (2012) 0.94
Profilin-1 phosphorylation directs angiocrine expression and glioblastoma progression through HIF-1α accumulation. Nat Cell Biol (2014) 0.94
Ultrasound-mediated drug delivery for cardiovascular disease. Expert Opin Drug Deliv (2013) 0.93
Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF-1α-neuropilin-1 axis. PLoS One (2012) 0.93
Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis. Microcirculation (2016) 0.91
B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One (2013) 0.90
Targeting the tumor vasculature to enhance T cell activity. Curr Opin Immunol (2015) 0.89
Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors. PLoS One (2012) 0.89
Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling. Oncogene (2013) 0.89
Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Cell Death Dis (2014) 0.89
The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches. PLoS One (2014) 0.89
Contemporary use of bevacizumab in ovarian cancer. Expert Opin Biol Ther (2012) 0.88
Low concentration of S100A8/9 promotes angiogenesis-related activity of vascular endothelial cells: bridges among inflammation, angiogenesis, and tumorigenesis? Mediators Inflamm (2012) 0.88
Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-targeted radiotracer 99mTc-3P-RGD2. J Pharmacol Exp Ther (2013) 0.88
SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness. PLoS One (2013) 0.88
Dynamic education of macrophages in different areas of human tumors. Cancer Microenviron (2012) 0.87
Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol (2012) 0.87
Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. J Clin Invest (2013) 0.87
RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. Cancers (Basel) (2012) 0.87
Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol (2015) 0.87
Discovery of novel drug targets and their functions using phenotypic screening of natural products. J Ind Microbiol Biotechnol (2015) 0.86
Dietary phenolic acids act as effective antioxidants in membrane models and in cultured cells, exhibiting proapoptotic effects in leukaemia cells. Oxid Med Cell Longev (2012) 0.86
CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells. Oncotarget (2014) 0.86
Upregulation of miR-107 Inhibits Glioma Angiogenesis and VEGF Expression. Cell Mol Neurobiol (2015) 0.86
Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis (2012) 0.85
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med (2016) 0.85
Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches. Best Pract Res Clin Anaesthesiol (2013) 0.85
EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma. Oncotarget (2014) 0.85
Epithelial to mesenchymal transition in arsenic-transformed cells promotes angiogenesis through activating β-catenin-vascular endothelial growth factor pathway. Toxicol Appl Pharmacol (2013) 0.85
Hydrogels to model 3D in vitro microenvironment of tumor vascularization. Adv Drug Deliv Rev (2014) 0.85
EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1. PLoS One (2013) 0.85
High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival. J Vasc Interv Radiol (2014) 0.85
Quantitative ex-vivo micro-computed tomographic imaging of blood vessels and necrotic regions within tumors. PLoS One (2012) 0.85
Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget (2015) 0.84
Glutamine fuels proliferation but not migration of endothelial cells. EMBO J (2017) 0.84
Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice. Oncotarget (2014) 0.84
Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer. Br J Cancer (2014) 0.84
Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. J Control Release (2013) 0.84
Targeted therapeutic nanotubes influence the viscoelasticity of cancer cells to overcome drug resistance. ACS Nano (2014) 0.84
Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling. Oncotarget (2016) 0.84
WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domain-containing protein tyrosine phosphatase 1. Oncotarget (2015) 0.83
Bone marrow-derived mesenchymal stem cell-secreted IL-8 promotes the angiogenesis and growth of colorectal cancer. Oncotarget (2015) 0.83
Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. Nat Commun (2015) 0.83
ERβ-dependent effects on uterine endothelial cells are cell specific and mediated via Sp1. Hum Reprod (2013) 0.83
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Immunity, inflammation, and cancer. Cell (2010) 28.27
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med (2001) 9.53
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell (2006) 9.32
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res (2006) 6.52
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science (2010) 6.01
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41
Trophic macrophages in development and disease. Nat Rev Immunol (2009) 5.37
Organ targeting in vivo using phage display peptide libraries. Nature (1996) 5.20
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature (2010) 4.85
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
MicroRNA function: multiple mechanisms for a tiny RNA? RNA (2005) 4.78
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
Integrin ligands at a glance. J Cell Sci (2006) 4.76
Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science (2008) 4.71
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol (2009) 4.53
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One (2006) 4.29
Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer (2008) 4.27
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Pathophysiological consequences of VEGF-induced vascular permeability. Nature (2005) 4.08
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02
Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell (2011) 4.02
MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer (2011) 3.91
Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med (1998) 3.85
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 3.82
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature (2010) 3.70
Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med (2008) 3.67
Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol (2010) 3.51
Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer (2010) 3.48
Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol (2011) 3.25
Vasculogenic mimicry and tumor angiogenesis. Am J Pathol (2000) 3.19
MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med (2010) 2.99
Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol (2001) 2.99
Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol (2001) 2.95
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
Endogenous inhibitors of angiogenesis. Cancer Res (2005) 2.88
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res (2007) 2.74
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell (2011) 2.70
Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci (2002) 2.62
Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol (2003) 2.58
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A (2008) 2.55
Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature (2004) 2.54
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A (2009) 2.41
AngiomiRs--key regulators of angiogenesis. Curr Opin Genet Dev (2009) 2.40
MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. Oncogene (2010) 2.37
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res (2008) 2.33
Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest (1991) 2.32
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res (2009) 2.23
Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. Dev Cell (2011) 2.23
Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol (2000) 2.21
Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol (2009) 2.20
Integrin and growth factor receptor crosstalk. Circ Res (2001) 2.18
Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem (2001) 2.11
Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent. J Nucl Med (2011) 2.11
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med (2009) 2.10
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res (2006) 1.96
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol (2010) 1.93
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery (2001) 1.90
Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J (2008) 1.88
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells (2009) 1.84
Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell (2008) 1.80
The integrin-growth factor receptor duet. J Cell Physiol (2007) 1.75
Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J (2003) 1.74
miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol (2010) 1.74
Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells (2010) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin αvβ₃. Blood (2011) 1.68
Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans (2004) 1.65
Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. Genes Dev (2011) 1.63
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Role of integrins in cell invasion and migration. Nat Rev Cancer (2002) 7.64
Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 4.78
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Pathophysiological consequences of VEGF-induced vascular permeability. Nature (2005) 4.08
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 3.82
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Differential regulation of cell motility and invasion by FAK. J Cell Biol (2003) 3.15
MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med (2010) 2.99
Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol (2002) 2.84
Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell (2011) 2.70
Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci (2002) 2.62
Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem (2005) 2.59
A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci U S A (2002) 2.58
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A (2008) 2.55
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med (2009) 2.10
Role of Raf in vascular protection from distinct apoptotic stimuli. Science (2003) 2.02
Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol (2003) 1.93
Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood (2008) 1.93
VEGF-induced vascular permeability is mediated by FAK. Dev Cell (2012) 1.85
Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. J Cell Biol (2008) 1.74
Gain-of-function mutational activation of human tRNA synthetase procytokine. Chem Biol (2007) 1.71
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67
ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci STKE (2002) 1.63
FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J (2002) 1.55
Formation of endothelial lumens requires a coordinated PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation. J Cell Sci (2009) 1.47
A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res (2002) 1.46
Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res (2009) 1.44
Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem (2002) 1.43
Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene (2003) 1.41
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest (2008) 1.39
αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med (2011) 1.33
Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med (2011) 1.31
Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med (2002) 1.20
Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res (2007) 1.18
A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med (2011) 1.17
Cooperation between VEGF and beta3 integrin during cardiac vascular development. Blood (2006) 1.17
RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proc Natl Acad Sci U S A (2009) 1.11
Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol (2014) 1.07
Matrix metalloproteinase 2-integrin alpha(v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: a computational time-lapse study. Mol Biol Cell (2008) 1.05
VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther (2009) 1.04
Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol (2012) 1.02
Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood (2011) 1.01
EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS One (2012) 1.00
MicroRNA-mediated regulation of the angiogenic switch. Curr Opin Hematol (2011) 1.00
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther (2008) 0.95
A critical role for Lyn kinase in strengthening endothelial integrity and barrier function. Blood (2013) 0.95
Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther (2011) 0.94
PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A (2013) 0.94
Loss of p53 compensates for alpha v-integrin function in retinal neovascularization. J Biol Chem (2002) 0.94
Emerging Role of Micro-RNAs in the Regulation of Angiogenesis. Genes Cancer (2011) 0.88
A Bit-role for integrins in apoptosis. Nat Cell Biol (2004) 0.87
Robo4 counteracts VEGF signaling. Nat Med (2008) 0.86
Derivation of vasculature from embryonic stem cells. Curr Protoc Stem Cell Biol (2010) 0.84
Agonizing integrin antagonists? Cancer Cell (2009) 0.83
Herpesvirus hijacks an integrin. Nat Cell Biol (2002) 0.83
A wake-up call for hibernating tumour cells. Nat Cell Biol (2013) 0.80
Suppressing NFAT increases VEGF signaling in hemangiomas. Cancer Cell (2008) 0.80
Building a better Trap. Proc Natl Acad Sci U S A (2003) 0.79
A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels. Liver Int (2011) 0.77
Monographs editor. Genes Cancer (2011) 0.75
Preface: a tribute to Dr. Judah Folkman. Methods Enzymol (2008) 0.75